Aadi Bioscience, Inc. (AADI) Reports In-Line Q3 EPS

Aadi Bioscience, Inc. (NASDAQ: AADI) reported Q3 EPS of ($0.46), in-line with the analyst estimate of ($0.46). Revenue for the quarter came in at $7.21 million versus the consensus estimate of $6.59 million.

For earnings history and earnings-related data on Aadi Bioscience, Inc. (AADI) click here.

You May Also Be Interested In

• William Blair on TransMedics Group (TMDX): 'We believe TransMedics’ second-quarter sales will exceed consensus estimates'
• Palo Alto Networks (PANW) PT Raised to $330 at FBN Securities
• Plaid said to mull U.S. IPO after reaching $8 billion valuation